A couple of recent studies suggest that DNA methyltransferase inhibitors, currently used in the treatment of hematologic cancers, increase the sensitivity of tumor cells to immune-checkpoint–inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Anthony E. Dear (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: